These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36403178)

  • 1. CRISPR/Cas9, a promising approach for the treatment of β-thalassemia: a systematic review.
    Khiabani A; Kohansal MH; Keshavarzi A; Shahraki H; Kooshesh M; Karimzade M; Gholizadeh Navashenaq J
    Mol Genet Genomics; 2023 Jan; 298(1):1-11. PubMed ID: 36403178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-Treatment of Erythroid Cells from β-Thalassemia Patients with CRISPR-Cas9-Based β
    Cosenza LC; Zuccato C; Zurlo M; Gambari R; Finotti A
    Genes (Basel); 2022 Sep; 13(10):. PubMed ID: 36292612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted deletion of BCL11A gene by CRISPR-Cas9 system for fetal hemoglobin reactivation: A promising approach for gene therapy of beta thalassemia disease.
    Khosravi MA; Abbasalipour M; Concordet JP; Berg JV; Zeinali S; Arashkia A; Azadmanesh K; Buch T; Karimipoor M
    Eur J Pharmacol; 2019 Jul; 854():398-405. PubMed ID: 31039344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR/Cas-based gene editing in therapeutic strategies for beta-thalassemia.
    Zeng S; Lei S; Qu C; Wang Y; Teng S; Huang P
    Hum Genet; 2023 Dec; 142(12):1677-1703. PubMed ID: 37878144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disruption of SOX6 gene using CRISPR/Cas9 technology for gamma-globin reactivation: An approach towards gene therapy of β-thalassemia.
    Shariati L; Rohani F; Heidari Hafshejani N; Kouhpayeh S; Boshtam M; Mirian M; Rahimmanesh I; Hejazi Z; Modarres M; Pieper IL; Khanahmad H
    J Cell Biochem; 2018 Nov; 119(11):9357-9363. PubMed ID: 30010219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Combination of CRISPR/Cas9 and iPSC Technologies in the Gene Therapy of Human β-thalassemia in Mice.
    Ou Z; Niu X; He W; Chen Y; Song B; Xian Y; Fan D; Tang D; Sun X
    Sci Rep; 2016 Sep; 6():32463. PubMed ID: 27581487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correction of β-thalassemia by CRISPR/Cas9 editing of the α-globin locus in human hematopoietic stem cells.
    Pavani G; Fabiano A; Laurent M; Amor F; Cantelli E; Chalumeau A; Maule G; Tachtsidi A; Concordet JP; Cereseto A; Mavilio F; Ferrari G; Miccio A; Amendola M
    Blood Adv; 2021 Mar; 5(5):1137-1153. PubMed ID: 33635334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in genome editing: the technology of choice for precise and efficient β-thalassemia treatment.
    Ali G; Tariq MA; Shahid K; Ahmad FJ; Akram J
    Gene Ther; 2021 Feb; 28(1-2):6-15. PubMed ID: 32355226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of an in vitro model of β-thalassemia using the CRISPR/Cas9 genome editing system.
    Ajami M; Atashi A; Kaviani S; Kiani J; Soleimani M
    J Cell Biochem; 2020 Feb; 121(2):1420-1430. PubMed ID: 31596028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Universal Approach to Correct Various HBB Gene Mutations in Human Stem Cells for Gene Therapy of Beta-Thalassemia and Sickle Cell Disease.
    Cai L; Bai H; Mahairaki V; Gao Y; He C; Wen Y; Jin YC; Wang Y; Pan RL; Qasba A; Ye Z; Cheng L
    Stem Cells Transl Med; 2018 Jan; 7(1):87-97. PubMed ID: 29164808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic correction of concurrent α- and β-thalassemia patient-derived pluripotent stem cells by the CRISPR-Cas9 technology.
    Li L; Yi H; Liu Z; Long P; Pan T; Huang Y; Li Y; Li Q; Ma Y
    Stem Cell Res Ther; 2022 Mar; 13(1):102. PubMed ID: 35255977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR/Cas9-mediated β-globin gene knockout in rabbits recapitulates human β-thalassemia.
    Yang Y; Kang X; Hu S; Chen B; Xie Y; Song B; Zhang Q; Wu H; Ou Z; Xian Y; Fan Y; Li X; Lai L; Sun X
    J Biol Chem; 2021; 296():100464. PubMed ID: 33639162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Editing an α-globin enhancer in primary human hematopoietic stem cells as a treatment for β-thalassemia.
    Mettananda S; Fisher CA; Hay D; Badat M; Quek L; Clark K; Hublitz P; Downes D; Kerry J; Gosden M; Telenius J; Sloane-Stanley JA; Faustino P; Coelho A; Doondeea J; Usukhbayar B; Sopp P; Sharpe JA; Hughes JR; Vyas P; Gibbons RJ; Higgs DR
    Nat Commun; 2017 Sep; 8(1):424. PubMed ID: 28871148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR/Cas9-based multiplex genome editing of BCL11A and HBG efficiently induces fetal hemoglobin expression.
    Han Y; Tan X; Jin T; Zhao S; Hu L; Zhang W; Kurita R; Nakamura Y; Liu J; Li D; Zhang Z; Fang X; Huang S
    Eur J Pharmacol; 2022 Mar; 918():174788. PubMed ID: 35093321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR-mediated gene modification of hematopoietic stem cells with beta-thalassemia IVS-1-110 mutation.
    Gabr H; El Ghamrawy MK; Almaeen AH; Abdelhafiz AS; Hassan AOS; El Sissy MH
    Stem Cell Res Ther; 2020 Sep; 11(1):390. PubMed ID: 32912325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One-step genetic correction of hemoglobin E/beta-thalassemia patient-derived iPSCs by the CRISPR/Cas9 system.
    Wattanapanitch M; Damkham N; Potirat P; Trakarnsanga K; Janan M; U-Pratya Y; Kheolamai P; Klincumhom N; Issaragrisil S
    Stem Cell Res Ther; 2018 Feb; 9(1):46. PubMed ID: 29482624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene Therapy and Genome Editing.
    Boulad F; Mansilla-Soto J; Cabriolu A; Rivière I; Sadelain M
    Hematol Oncol Clin North Am; 2018 Apr; 32(2):329-342. PubMed ID: 29458735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: An approach for treating sickle cell disease and β-thalassemia.
    Ye L; Wang J; Tan Y; Beyer AI; Xie F; Muench MO; Kan YW
    Proc Natl Acad Sci U S A; 2016 Sep; 113(38):10661-5. PubMed ID: 27601644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correction of Hemoglobin E/Beta-Thalassemia Patient-Derived iPSCs Using CRISPR/Cas9.
    Wattanapanitch M
    Methods Mol Biol; 2021; 2211():193-211. PubMed ID: 33336279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient CRISPR-Cas9-based genome editing of β-globin gene on erythroid cells from homozygous β
    Cosenza LC; Gasparello J; Romanini N; Zurlo M; Zuccato C; Gambari R; Finotti A
    Mol Ther Methods Clin Dev; 2021 Jun; 21():507-523. PubMed ID: 33997100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.